
Hypertension - Drug Pipeline Landscape, 2023
Description
Hypertension - Drug Pipeline Landscape, 2023
Hypertension also known as high blood pressure is a condition where the force of blood pushing against the arterial walls of heart is consistently higher than the normal. Hypertension can be identified as primary/essential (without a known cause such as age, genetics, sedentary lifestyle, alcohol consumption, high sodium intake etc.) and secondary (due to an underlying condition as its cause such as congenital heart defects, kidney diseases, endocrinal issues, side effects of drugs etc).
The most common causes of Hypertension include underlying diseases, side effects of medications, age, overweight, genetics, high sodium intake, alcohol consumption, stress, lifestyle, pregnancy.
Symptoms include shortness of breath, early morning headaches, nose bleeding, irregular heart rhythms, fatigue, nausea, vomiting, confusion, anxiety, chest pain, and muscle tremors. Most people with high blood pressure have no signs or symptoms of it, hence given name as "silent killer".
Hypertension can be diagnosed if the systolic blood pressure readings are greater than or equal to 140 mmHg and/or the diastolic blood pressure readings are greater than or equal to 90 mmHg measured on two different days.
The most common treatments for Hypertension are vasodilators, renin inhibitors, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, alpha/beta blockers, diuretics, and/or lifestyle changes such as physical activity, healthy salt diet.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Hypertension treatment such as IN-C008, Yutrepia, Aprocitentan, MK-5475, Ralinepag and others. Key players involved in the development of therapies to treat Hypertension are HK inno.N Corporation, Liquidia Technologies Inc, Idorsia Pharmaceuticals Ltd, Merck Inc, United Therapeutics and others. Three drugs are under late-stage Pre-Registration, thirty-eight drugs are under Phase III clinical trials, thirty-three drugs are in Phase II clinical trials and some other drugs are under Phase I, Preclinical, Discovery and Unknown stages of development.
In December 2022, Idorsia Pharmaceuticals Ltd submitted a New Drug Application to the US FDA for Aprocitentan for the treatment of patients with difficult-to control (resistant) hypertension.
Report Highlights
Global Insight Service's, Hypertension - Drug Pipeline Landscape, 2023 report provides an overview of the Hypertension pipeline drugs. This report covers detailed insights on Anti-hypertension drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Anti-hypertension pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Hypertension also known as high blood pressure is a condition where the force of blood pushing against the arterial walls of heart is consistently higher than the normal. Hypertension can be identified as primary/essential (without a known cause such as age, genetics, sedentary lifestyle, alcohol consumption, high sodium intake etc.) and secondary (due to an underlying condition as its cause such as congenital heart defects, kidney diseases, endocrinal issues, side effects of drugs etc).
The most common causes of Hypertension include underlying diseases, side effects of medications, age, overweight, genetics, high sodium intake, alcohol consumption, stress, lifestyle, pregnancy.
Symptoms include shortness of breath, early morning headaches, nose bleeding, irregular heart rhythms, fatigue, nausea, vomiting, confusion, anxiety, chest pain, and muscle tremors. Most people with high blood pressure have no signs or symptoms of it, hence given name as "silent killer".
Hypertension can be diagnosed if the systolic blood pressure readings are greater than or equal to 140 mmHg and/or the diastolic blood pressure readings are greater than or equal to 90 mmHg measured on two different days.
The most common treatments for Hypertension are vasodilators, renin inhibitors, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, alpha/beta blockers, diuretics, and/or lifestyle changes such as physical activity, healthy salt diet.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Hypertension treatment such as IN-C008, Yutrepia, Aprocitentan, MK-5475, Ralinepag and others. Key players involved in the development of therapies to treat Hypertension are HK inno.N Corporation, Liquidia Technologies Inc, Idorsia Pharmaceuticals Ltd, Merck Inc, United Therapeutics and others. Three drugs are under late-stage Pre-Registration, thirty-eight drugs are under Phase III clinical trials, thirty-three drugs are in Phase II clinical trials and some other drugs are under Phase I, Preclinical, Discovery and Unknown stages of development.
In December 2022, Idorsia Pharmaceuticals Ltd submitted a New Drug Application to the US FDA for Aprocitentan for the treatment of patients with difficult-to control (resistant) hypertension.
Report Highlights
Global Insight Service's, Hypertension - Drug Pipeline Landscape, 2023 report provides an overview of the Hypertension pipeline drugs. This report covers detailed insights on Anti-hypertension drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Anti-hypertension pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
313 Pages
- 1. Introduction
- 1.1 Hypertension - Pipeline Drugs, 2023 - Coverage
- 2. Disease Overview - Hypertension
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3. Hypertension - Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2023
- 3.3 Products under Development by Companies, 2023
- 4. Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.3 Assessment by Route of Administration
- 5. Drug Profiles
- 5.1 Late Stage Drugs – Pre-Registration
- 5.1.1 Arocitentan
- 5.1.2 IN-C008
- 5.1.3 Yutrepia
- 5.2 Clinical Stage Drugs – Phase III
- 5.2.1 AD-202
- 5.2.2 AD-207
- 5.2.3 AD-2071
- 5.2.4 AD-2073
- 5.2.5 ATB-101
- 5.2.6 Atorvastatin/Perindopril
- 5.2.7 Autologous Endothelial Progenitor Cells (EPCs) Transfected With Human Endothelial NO-synthase
- 5.2.8 AV-101
- 5.2.9 BR1010
- 5.2.10 CKD-333
- 5.2.11 CKD-386
- 5.2.12 Clevidipine Butyrate
- 5.2.13 Edoxaban
- 5.2.14 Ezetimibe/Rosuvastatin and Telmisartan
- 5.2.15 Firibastat
- 5.2.16 FNP 202
- 5.2.17 GMRx2
- 5.2.18 HCP1904-1
- 5.2.19 HCP1904-2
- 5.2.20 HCP1904-3
- 5.2.21 HCP2102
- 5.2.22 IN-C036
- 5.2.23 Inhaled Nitric Oxide
- 5.2.24 Irbesartan/Amlodipine
- 5.2.25 KBP-5074
- 5.2.26 KW-3357
- 5.2.27 L606
- 5.2.28 LivaloVA
- 5.2.29 Macitentan (Pediatric)
- 5.2.30 Macitentan and Tadalafil FDC (Global)
- 5.2.31 MK-5475
- 5.2.32 MT-2765
- 5.2.33 PRM-125
- 5.2.34 Ralinepag
- 5.2.35 Selexipag
- 5.2.36 Sotatercept
- 5.2.37 SPH3127
- 5.2.38 Treprostinil Sodium
- 5.3 Clinical Stage Drugs – Phase II
- 5.3.1 AD-209
- 5.3.2 AGSAVI
- 5.3.3 Azilsartan Medoxomil and Amlodipine
- 5.3.4 Baxdrostat
- 5.3.5 BI 685509
- 5.3.6 CS1
- 5.3.7 D064
- 5.3.8 D701
- 5.3.9 HCP1803
- 5.3.10 Hymecromone
- 5.3.11 Ifetroban
- 5.3.12 ION904
- 5.3.13 IONIS-AGT-LRx
- 5.3.14 Levosimendan
- 5.3.15 Losartan/chlorthalidone
- 5.3.16 LTP001
- 5.3.17 MLS-101
- 5.3.18 N-003
- 5.3.19 Nitrosooxypropanol
- 5.3.20 Olaparib
- 5.3.21 Olmesartan/Indapamide
- 5.3.22 Pemziviptadil
- 5.3.23 Presendin
- 5.3.24 Rodatristat Ethyl
- 5.3.25 RT234
- 5.3.26 Seralutinib
- 5.3.27 Tacrolimus
- 5.3.28 TNX-201
- 5.3.29 TPN171H
- 5.3.30 Treprostinil Palmitil
- 5.2.31 Ularitide
- 5.3.32 Zamicastat
- 5.3.33 Zilebesiran
- 5.4 Clinical Stage Drugs – Phase I
- 5.4.1 ABI-009
- 5.4.2 AD-210
- 5.4.3 AER-901
- 5.4.4 AJU-C52
- 5.4.5 ANPA-0073
- 5.4.6 Apabetalone
- 5.4.7 BR1015 (Incrementally Modified)
- 5.4.8 BR1017
- 5.4.9 BR1018
- 5.4.10 Brilaroxazine
- 5.4.11 C21
- 5.4.12 CAM2043
- 5.4.13 CKD-348
- 5.4.14 CKD-385
- 5.4.15 GMA301
- 5.4.16 ID140009
- 5.4.17 KER-012
- 5.4.18 LAM-001
- 5.4.19 MANP
- 5.4.20 NTP-42
- 5.4.21 Prostacyclin Receptor Agonist
- 5.4.22 REGN9035/REGN5381
- 5.4.23 RemoPro
- 5.4.24 SIF-019
- 5.4.25 SP0001
- 5.4.26 XXB750
- 5.5 Early Stage Drugs – Preclinical
- 5.5.1 ALT-100
- 5.5.2 Antliabio 111
- 5.5.3 Antliabio 112
- 5.5.4 Belapectin
- 5.5.5 BZ371
- 5.5.6 CAR adjuvant SL & IV
- 5.5.7 CAR Imaging agents
- 5.5.8 CAR Liposomes
- 5.5.9 Firibastat + ACE inhibitor
- 5.5.10 FNP 320
- 5.5.11 GMA306
- 5.5.12 GMA307
- 5.5.13 GXV-002
- 5.5.14 INV-100
- 5.5.15 INV-200
- 5.5.16 MFC-1040
- 5.5.17 MGX292
- 5.5.18 MN-08
- 5.5.19 NTP-48
- 5.5.20 PB6440
- 5.5.21 PT001
- 5.5.22 QGC006
- 5.5.23 QGC606
- 5.5.24 R-107
- 5.5.25 RBM-011
- 5.5.26 REC-1886
- 5.5.27 SUL-150
- 5.5.28 TOPV-122
- 5.5.29 TP-20
- 5.5.30 Undisclosed Integrin Inhibitor
- 5.5.31 VRN-13
- 5.5.32 VTA-04
- 5.5.33 ZM-A001
- 5.6 Early Stage Drugs – Discovery
- 5.6.1 AD-107
- 5.6.2 AD-108
- 5.6.3 AD-110
- 5.6.4 AD-219
- 5.6.5 AD-222
- 5.6.6 AR001
- 5.6.7 Nrf-2 Activator
- 5.7 Unknown Stage Drugs
- 5.7.1 APT102
- 6. Key Regulatory Designations
- 7. Key Deals
- 8. Key Upcoming Milestones
- 9. Key Companies Involved
- 9.1 Aadi Bioscience, Inc.
- 9.2 Addpharma Inc.
- 9.3 Aeon Respire Inc
- 9.4 Aerami Therapeutics
- 9.5 Aerovate Therapeutics
- 9.6 Ahn-Gook Pharmaceuticals Co Ltd
- 9.7 AI Therapeutics
- 9.8 AJU Pharm Co., Ltd.
- 9.9 Alnylam Pharmaceuticals
- 9.10 Altavant Sciences GmbH
- 9.11 Annapurna Bio Pty Ltd
- 9.12 Antlia Bioscience Inc
- 9.13 Apaxen
- 9.14 APT Therapeutics Inc
- 9.15 Aqualung Therapeutics Corp
- 9.16 AstraZeneca
- 9.17 Attgeno AB
- 9.18 ATXA Therapeutics
- 9.19 Autotelicbio
- 9.20 Bellerophon
- 9.21 Bial - Portela C S.A.
- 9.22 Biozeus Pharmaceutical SA
- 9.23 Boehringer Ingelheim
- 9.24 Boryung Pharmaceutical Co., Ltd
- 9.25 Brainfarma Industria Quimica e Farmaceutica S/A
- 9.26 C4X Discovery Holdings Plc
- 9.27 Camurus AB
- 9.28 Cardiorentis AG
- 9.29 Celltrion
- 9.30 Centessa Pharmaceuticals
- 9.31 Cereno Scientific AB
- 9.32 Chong Kun Dang Pharmaceutical
- 9.33 CinCor Pharma, Inc.
- 9.34 Claritas Pharmaceuticals
- 9.35 Cumberland Pharmaceuticals
- 9.36 Daiichi Sankyo Co., Ltd.
- 9.37 E-Star BioTech, LLC
- 9.38 Ferrer Internacional S.A.
- 9.39 Galectin Therapeutics Inc
- 9.40 George Medicines PTY Limited
- 9.41 GEXVal
- 9.42 Gmax Biopharm LLC
- 9.43 Gossamer Bio Inc
- 9.44 Guangzhou Magpie Pharmaceutical Co Ltd
- 9.45 Halo Biosciences
- 9.46 Handok Inc.
- 9.47 Hanlim Pharm. Co., Ltd.
- 9.48 Hanmi Pharmaceutical Company Limited
- 9.49 HK inno.N Corporation
- 9.50 Idorsia Pharmaceuticals Ltd
- 9.51 IlDong Pharmaceutical Co Ltd
- 9.52 Insmed Incorporated
- 9.53 INVENT Pharmaceuticals Inc
- 9.54 Invex Therapeutics Ltd
- 9.55 Ionis Pharmaceuticals, Inc.
- 9.56 Johnson & Johnson
- 9.57 JW Pharmaceutical
- 9.58 KBP Biosciences
- 9.59 Keros Therapeutics
- 9.60 Kyowa Kirin Co., Ltd
- 9.61 Laboratorios Silanes S.A. de C.V.
- 9.62 Liquidia Technologies, Inc.
- 9.63 Merck Inc
- 9.64 Mineralys Therapeutics Inc.
- 9.65 Mitsubishi Tanabe Pharma
- 9.66 Morphic Therapeutic Inc
- 9.67 Nanjing Yoko Biomedical Co., Ltd.
- 9.68 Noorik Biopharmaceuticals AG
- 9.69 Northern Therapeutics
- 9.70 Novartis
- 9.71 Pharmosa Biopharm Inc
- 9.72 PhaseBio Pharmaceuticals Inc
- 9.73 PRM Pharma, LLC
- 9.74 PulmoSIM Therapeutics
- 9.75 Quantum Genomics SA
- 9.76 Recursion Pharmaceuticals Inc
- 9.77 Regeneron Pharmaceuticals
- 9.78 Respira Therapeutics, Inc.
- 9.79 Resverlogix Corp
- 9.80 Reviva Pharmaceuticals
- 9.81 Ribomic
- 9.82 SciPharm SA RL
- 9.83 Sentan Pharma Inc
- 9.84 Servier
- 9.85 Shanghai Pharmaceuticals Holding Co., Ltd
- 9.86 Sulfateq BV
- 9.87 Systimmune Inc
- 9.88 Tenax Therapeutics, Inc.
- 9.89 Topadur Pharma AG
- 9.90 United Therapeutics
- 9.91 Vascular BioSciences
- 9.92 VasThera Co Ltd
- 9.93 Vicore Pharma
- 9.94 Vigonvita Life Sciences
- 9.95 Vivus LLC
- 9.96 Voronoi Group
- 9.97 Zymedi
- 10. Dormant Drugs
- 10.1 Inactive Drugs
- 10.2 Discontinued Drugs
- 11. Appendix
- List of Tables
- Table 1.1 Number of Products under Development by Hypertension
- Table 1.2 Number of Products under Development by Companies
- Table 1.3 Products under Development by Companies
- Table 1.4 Products by Targets
- Table 1.5 Products by Mechanism of Action
- Table 1.6 Products by Molecule Type
- Table 1.7 Products by Route of Administration
- Table 2.1 Clinical Trial Details - AD-2071/Addpharma Inc.
- Table 2.2 Clinical Trial Details - AD-2073/Addpharma Inc.
- Table 2.3 Clinical Trial Details - Aprocitentan/Idorsia Pharmaceuticals Ltd
- Table 2.4 Clinical Trial Details - ATB-101/Autotelicbio
- Table 2.5 Clinical Trial Details - Atorvastatin/Perindopril/Servier
- Table 2.6 Clinical Trial Details - Autologous Endothelial Progenitor Cells (EPCs) Transfected With Human Endothelial NO-synthase/Northern Therapeutics
- Table 2.7 Clinical Trial Details - AV-101/Aerovate Therapeutics
- Table 2.8 Clinical Trial Details - BR1010/Boryung Pharmaceutical Co., Ltd
- Table 2.9 Clinical Trial Details - CKD-333/Chong Kun Dang Pharmaceutical
- Table 2.10 Clinical Trial Details - CKD-386/Chong Kun Dang Pharmaceutical
- Table 2.11 Clinical Trial Details - Clevidipine Butyrate/Nanjing Yoko Biomedical Co., Ltd.
- Table 2.12 Clinical Trial Details - Edoxaban/Daiichi Sankyo Co., Ltd.
- Table 2.13 Clinical Trial Details - Ezetimibe/Rosuvastatin and Telmisartan/Hanlim Pharm. Co., Ltd.
- Table 2.14 Clinical Trial Details - Firibastat/Quantum Genomics SA
- Table 2.15 Clinical Trial Details - GMRx2/George Medicines PTY Limited
- Table 2.16 Clinical Trial Details - HCP1904-1/Hanmi Pharmaceutical Company Limited
- Table 2.17 Clinical Trial Details - HCP1904-2/Hanmi Pharmaceutical Company Limited
- Table 2.18 Clinical Trial Details - HCP1904-3/Hanmi Pharmaceutical Company Limited
- Table 2.19 Clinical Trial Details - HCP2102/Hanmi Pharmaceutical Company Limited
- Table 2.20 Clinical Trial Details - Inhaled Nitric Oxide/Bellerophon
- Table 2.21 Clinical Trial Details - Irbesartan/Amlodipine/Handok Inc.
- Table 2.22 Clinical Trial Details - KBP-5074/KBP Biosciences
- Table 2.23 Clinical Trial Details - KW-3357/Kyowa Kirin Co., Ltd
- Table 2.24 Clinical Trial Details - L606/Pharmosa Biopharm Inc
- Table 2.25 Clinical Trial Details - LivaloVA/JW Pharmaceutical
- Table 2.26 Clinical Trial Details - Macitentan (Pediatric)/Johnson & Johnson
- Table 2.27 Clinical Trial Details - Macitentan and Tadalafil FDC (Global)/Johnson & Johnson
- Table 2.28 Clinical Trial Details - MK-5475/Merck
- Table 2.29 Clinical Trial Details - PRM-125/PRM Pharma, LLC
- Table 2.30 Clinical Trial Details - Ralinepag/United Therapeutics
- Table 2.31 Clinical Trial Details - Selexipag/Johnson & Johnson
- Table 2.32 Clinical Trial Details - Sotatercept/Merck
- Table 2.33 Clinical Trial Details - SPH3127/Shanghai Pharmaceuticals Holding Co., Ltd
- Table 2.34 Clinical Trial Details - Treprostinil Sodium/SciPharm SÃ RL
- Table 2.35 Clinical Trial Details - AD-209/Addpharma Inc.
- Table 2.36 Clinical Trial Details - AGSAVI/Ahn-Gook Pharmaceuticals Co.,Ltd
- Table 2.37 Clinical Trial Details - Azilsartan Medoxomil and amlodipine/Celltrion
- Table 2.38 Clinical Trial Details - Baxdrostat/CinCor Pharma, Inc.
- Table 2.39 Clinical Trial Details - BI 685509/Boehringer Ingelheim
- Table 2.40 Clinical Trial Details - CS1/Cereno Scientific AB
- Table 2.41 Clinical Trial Details - D064/Chong Kun Dang Pharmaceutical
- Table 2.42 Clinical Trial Details - D701/Chong Kun Dang Pharmaceutical
- Table 2.43 Clinical Trial Details - HCP1803/Hanmi Pharmaceutical Company Limited
- Table 2.44 Clinical Trial Details - Hymecromone/Halo Biosciences
- Table 2.45 Clinical Trial Details - Ifetroban/Cumberland Pharmaceuticals
- Table 2.46 Clinical Trial Details - ION904/Ionis Pharmaceuticals, Inc.
- Table 2.47 Clinical Trial Details - IONIS-AGT-LRx/Ionis Pharmaceuticals, Inc.
- Table 2.48 Clinical Trial Details - Levosimendan/Tenax Therapeutics, Inc.
- Table 2.49 Clinical Trial Details - Losartan/chlorthalidone/Laboratorios Silanes S.A. de C.V.
- Table 2.50 Clinical Trial Details - LTP001/Novartis
- Table 2.51 Clinical Trial Details - MLS-101/Mineralys Therapeutics Inc.
- Table 2.52 Clinical Trial Details - N-003/Noorik Biopharmaceuticals AG
- Table 2.53 Clinical Trial Details - Nitrosooxypropanol/Attgeno AB
- Table 2.54 Clinical Trial Details - Olaparib/AstraZeneca
- Table 2.55 Clinical Trial Details - Olmesartan/Indapamide/Brainfarma Industria Quimica e Farmaceutica S/A
- Table 2.56 Clinical Trial Details - Pemziviptadil/PhaseBio Pharmaceuticals Inc.
- Table 2.57 Clinical Trial Details - Presendin/Invex Therapeutics Ltd
- Table 2.58 Clinical Trial Details - Rodatristat Ethyl/Altavant Sciences GmbH
- Table 2.59 Clinical Trial Details - RT234/Respira Therapeutics, Inc.
- Table 2.60 Clinical Trial Details - Seralutinib/Gossamer Bio Inc
- Table 2.61 Clinical Trial Details - TPN171H/Vigonvita Life Sciences
- Table 2.62 Clinical Trial Details - Treprostinil Palmitil/Insmed Incorporated
- Table 2.63 Clinical Trial Details - Ularitide/Cardiorentis AG
- Table 2.64 Clinical Trial Details - Zamicastat/Bial - Portela C S.A.
- Table 2.65 Clinical Trial Details - Zilebesiran/Alnylam Pharmaceuticals
- Table 2.66 Clinical Trial Details - ABI-009/Aadi Bioscience, Inc.
- Table 2.67 Clinical Trial Details - AJU-C52/AJU Pharm Co., Ltd.
- Table 2.68 Clinical Trial Details - ANPA-0073/Annapurna Bio Pty Ltd
- Table 2.69 Clinical Trial Details - Apabetalone/Resverlogix Corp
- Table 2.70 Clinical Trial Details - CKD-348/Chong Kun Dang Pharmaceutical
- Table 2.71 Clinical Trial Details - CKD-385/Chong Kun Dang Pharmaceutical
- Table 2.72 Clinical Trial Details - GMA301/Gmax Biopharm LLC.
- Table 2.73 Clinical Trial Details - ID140009/IlDong Pharmaceutical Co Ltd
- Table 2.74 Clinical Trial Details - KER-012/Keros Therapeutics
- Table 2.75 Clinical Trial Details - MANP/E-Star BioTech, LLC
- Table 2.76 Clinical Trial Details - NTP-42/ATXA Therapeutics
- Table 2.77 Clinical Trial Details - Prostacyclin Receptor Agonist/Johnson & Johnson
- Table 2.78 Clinical Trial Details - REGN9035/REGN5381/Regeneron Pharmaceuticals
- Table 2.79 Clinical Trial Details - SIF-019/Systimmune Inc
- Table 2.80 Clinical Trial Details - XXB750/Novartis
- Table 3.1 Regulatory Designations
- Table 4.1 Inactive Drugs
- Table 4.2 Discontinued Drugs
- List of Figures
- Figure 1.1 Number of Products under Development for Hypertension, 2023
- Figure 1.2 Products by Top 5 Targets and Stage of Development for Hypertension, 2023
- Figure 1.3 Products by Top 5 Mechanism of Action for Hypertension, 2023
- Figure 1.4 Products by Top 5 Molecule Type for Hypertension, 2023
- Figure 1.5 Products by Top 5 Route of Administration for Hypertension, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.